Plain-English translation of NCT06532799 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called TIL therapy combined with (Keytruda) for patients with advanced or metastatic stomach and esophageal cancer. Doctors will remove immune cells from your tumor, expand them in a laboratory, and then infuse them back into your body along with additional immunotherapy to help your immune system fight the cancer. This personalized approach harnesses your own body's defenses to target and destroy cancer cells.
Stomach and esophageal cancers that have spread or come back after standard treatment have very few options and carry a poor outlook. This new treatment aims to offer hope to patients who have run out of conventional choices by leveraging the immune system in a novel way.
You likely qualify if…
You likely don't qualify if…
You will have a biopsy or surgery to collect immune cells from your tumor. Then you'll receive several doses of preparatory medications over about a week to ready your body for the treatment. On day 0, doctors will infuse your expanded immune cells back into you, followed by additional immunotherapy medications given over the following weeks and months. You'll need hospitalization during the initial treatment phase and will have frequent follow-up visits to check how you're responding and monitor for any side effects. The entire treatment and follow-up period will last about a year.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China